AACR: Revolution Medicines Data, NCI Director, and Wildfires in 30 Seconds

Angus Cheng covers all issues broadly related to cancer, including medicines, policy, science and stocks. She joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His work has been recognized with the national Edward R. Murrow Award and the June L. Biedler Award for Cancer Journalism, among others. You can access Angus.08 on Signal.

Damian Garde covers the global pharmaceutical industry as a general live and feature journalism reporter and contributes to STAT’s industry-leading events.

You’re reading AACR in 30, the web version of STAT’s pop-up newsletter. This is your guide to what’s happening at the American Association for Cancer Research annual meeting. Sign up here.

The big AACR is coming to an end. We look forward to seeing you at our live event on Tuesday night. Clearly, Revolution Medicines and KRAS are big topics at the conference. Last year’s AACR was dominated by major concerns about what would happen to cancer research funding under the Trump administration. This year, NCI’s new director sought to allay researchers’ fears. Read more!

Good results with Revolution Medicine’s KRAS drug

Last week, researchers working with the biotech company Revolution Medicine announced some surprising news. The experimental drug dalaxone lasib more than doubled survival times for second-line pancreatic cancer patients compared to chemotherapy. But it only means extending the median survival time for this terrible disease by six months.

STAT+ exclusive story